Aldara for the Treatment of Extensive Alopecia Areata

• Status: Completed
• Trial end date: 2002-08-01
• Target enrollment: 0
• Participant gender: All

Summary

We propose to examine the efficacy and tolerability of Aldara Cream 5% for the treatment of extensive alopecia areata. Aldara is a immune-response modifier. The drug induces the production of cytokines which are small, hormone-like proteins involved in cellular communication during immune responses. We hypothesize that this drug will effect the inflammatory cells present around hair follicles in patients with alopecia areata.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Hordinsky, Maria K., MD
• Collaborators: 3M; National Alopecia Areata Foundation
• Treatments: Imiquimod

Criteria

Inclusion Criteria:

• Must give written informed consent.

• Must be 18 years of age, male or female of any race.

• Subjects must have extensive scalp alopecia areata (>95% involvement) of less than 2 years duration.

• In good general and mental health based on a medical history and physical exam.

• Patient must be willing to refrain from all other alopecia areata treatments during the course of the study.

• Must agree to shampoo daily with Free and Clear shampoo.

Exclusion Criteria:

• History of any illness or condition that in the opinion of the investigator might confound the results of the study or pose additional risk in administering the drug to the patient.

• Significant abnormalities on screening clinical examination.

• Previous use of Aldara Cream 5%

• History of drug or alcohol abuse.

• Use of ultraviolet radiation, including tanning beds and PUVA therapy for treatment of acne, psoriasis, or any other skin condition within 2 months prior to study initiation.

• Use of systemic or topical glucocorticoids, corticosteroids. estrogenic, progestogenic, androgenic, or antiandrogen drugs, cyclosporine, FK506 or immunotherapy with DNCB, SADBE, or DCP within 6 months of study initiation.

• Use of a topical medication within six weeks prior to the study.

• Alterations in thyroid medication within 6 months of study initiation.

• Pregnant or nursing females.